{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:12:37Z","timestamp":1790845957178,"version":"4.1.0"},"reference-count":95,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides constitute a novel class of heterocyclic compounds with broad biological activity, including anticancer properties. Investigated in this study, MM-compounds (MM134, MM136, MM137, and MM139) exhibited cytotoxic and proapoptotic activity against cancer cell lines (BxPC-3, PC-3, and HCT-116) in nanomolar concentrations without causing cytotoxicity in normal cells (L929 and WI38). In silico predictions indicate that tested compounds exhibit favorable pharmacokinetic profiles and may exert anticancer activity through the inhibition of BTK kinase, the AKT-mTOR pathway and PD1-PD-L1 interaction. Our findings point out that these sulfonamide derivatives may constitute a source of new anticancer drugs after optimization.<\/jats:p>","DOI":"10.3390\/ijms23115892","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T22:04:06Z","timestamp":1653429846000},"page":"5892","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Preparation of Novel Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides and Their Experimental and Computational Biological Studies"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8616-3825","authenticated-orcid":false,"given":"Mateusz","family":"Kciuk","sequence":"first","affiliation":[{"name":"Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland"},{"name":"Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4037-5475","authenticated-orcid":false,"given":"Somdutt","family":"Mujwar","sequence":"additional","affiliation":[{"name":"M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University) Mullana, Ambala 133207, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-3336","authenticated-orcid":false,"given":"Anna","family":"Szymanowska","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Siedlce University of Natural Sciences and Humanities, 08-110 Siedlce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8109-6478","authenticated-orcid":false,"given":"Beata","family":"Marciniak","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2517-9898","authenticated-orcid":false,"given":"Karol","family":"Bukowski","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9884-6068","authenticated-orcid":false,"given":"Mariusz","family":"Mojzych","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Siedlce University of Natural Sciences and Humanities, 08-110 Siedlce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2859-9839","authenticated-orcid":false,"given":"Renata","family":"Kontek","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00253-012-4279-6","article-title":"Monascus-fermented red mold rice exhibits cytotoxic effect and induces apoptosis on human breast cancer cells","volume":"97","author":"Lee","year":"2012","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0006-2952(99)00035-0","article-title":"Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation","volume":"58","author":"Hatse","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/cr900028p","article-title":"Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer","volume":"109","author":"Parker","year":"2009","journal-title":"Chem. Rev."},{"key":"ref_4","unstructured":"Pizzorno, G., Diasio, R.B., and Cheng, Y.-C. (2022, May 01). Pyrimidine and Purine Antimetabolites, Holland-Frei Cancer Medicine, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK13028\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.drup.2010.09.001","article-title":"Apoptosis assays for quantifying the bioactivity of anticancer drug products","volume":"13","author":"Brunelle","year":"2010","journal-title":"Drug Resist. Updates"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cbin.11137","article-title":"Cell death: A review of the major forms of apoptosis, necrosis and autophagy","volume":"43","year":"2019","journal-title":"Cell Biol. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Crowley, L., Marfell, B.J., Scott, A.P., and Waterhouse, N.J. (2016). Quantitation of Apoptosis and Necrosis by Annexin V Binding, Propidium Iodide Uptake, and Flow Cytometry. Cold Spring Harb. Protoc., 2016.","DOI":"10.1101\/pdb.prot087288"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2174\/0929867033456585","article-title":"Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: Synthesis and antiproliferative evaluation","volume":"10","author":"Bouchain","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2174\/092986708783497300","article-title":"Role of sulfonamide group in matrix metalloproteinase inhibitors","volume":"15","author":"Cheng","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","article-title":"An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site","volume":"29","author":"Lu","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1016\/j.bmc.2014.10.009","article-title":"Synthesis of pyrazolo[4,3-e][1,2,4]triazine sulfonamides, novel Sildenafil analogs with tyrosinase inhibitory activity","volume":"22","author":"Mojzych","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14756366.2016.1238362","article-title":"Synthesis of chiral pyrazolo[4,3-e][1,2,4]triazine sulfonamides with tyrosinase and urease inhibitory activity","volume":"32","author":"Mojzych","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejmech.2014.03.054","article-title":"Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines","volume":"78","author":"Mojzych","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_15","first-page":"80","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"63","author":"Fendrich","year":"2006","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bernat, Z., Szymanowska, A., Kciuk, M., Kotwica-Mojzych, K., and Mojzych, M. (2020). Review of the Synthesis and Anticancer Properties of Pyrazolo[4,3-e][1,2,4]triazine Derivatives. Molecules, 25.","DOI":"10.3390\/molecules25173948"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.bmcl.2004.02.008","article-title":"Imidazo[1,2-b]pyridazines: A potent and selective class of cyclin-dependent kinase inhibitors","volume":"14","author":"Byth","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1016\/j.bmcl.2007.05.041","article-title":"Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2","volume":"17","author":"Nie","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_19","first-page":"1830","article-title":"Protein Kinase CK2 in Health and Disease","volume":"66","author":"Filhol","year":"2009","journal-title":"Exp."},{"key":"ref_20","first-page":"87","article-title":"Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3","volume":"34","author":"Benitez","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2174\/0929867033457647","article-title":"Anticancer and Antiviral Sulfonamides","volume":"10","author":"Scozzafava","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1080\/14756366.2022.2052868","article-title":"Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies","volume":"37","author":"Kciuk","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.bmc.2014.03.029","article-title":"Pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors with antitumor activity","volume":"22","author":"Mojzych","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.bmc.2015.02.026","article-title":"New approaches to the synthesis of sildenafil analogues and their enzyme inhibitory activity","volume":"23","author":"Mojzych","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/14756366.2021.1879803","article-title":"Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer","volume":"36","author":"Hermanowicz","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hermanowicz, J., Pawlak, K., Sieklucka, B., Czarnomysy, R., Kwiatkowska, I., Kazberuk, A., Surazynski, A., Mojzych, M., and Pawlak, D. (2021). MM-129 as a Novel Inhibitor Targeting PI3K\/AKT\/mTOR and PD-L1 in Colorectal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13133203"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: Clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5858\/arpa.2016-0361-RA","article-title":"Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)\/PD-L1 Blockade: A Key Player Against Various Cancers","volume":"141","author":"Guan","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.soc.2013.06.008","article-title":"Targeting the PI3-Kinase\/Akt\/mTOR Signaling Pathway","volume":"22","author":"Hassan","year":"2013","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1242\/dev.137075","article-title":"Proliferation, survival and metabolism: The role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination","volume":"143","author":"Yu","year":"2016","journal-title":"Development"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1039\/C5MB00101C","article-title":"The PI3K\/AKT\/mTOR interactive pathway","volume":"11","author":"Ersahin","year":"2015","journal-title":"Mol. BioSyst."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR Signaling in Cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hermanowicz, J.M., Kalaska, B., Pawlak, K., Sieklucka, B., Miklosz, J., Mojzych, M., and Pawlak, D. (2021). Preclinical Toxicity and Safety of MM-129\u2014First-in-Class BTK\/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081222"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gornowicz, A., Szymanowska, A., Mojzych, M., Czarnomysy, R., Bielawski, K., and Bielawska, A. (2021). The Anticancer Action of a Novel 1,2,4-Triazine Sulfonamide Derivative in Colon Cancer Cells. Molecules, 26.","DOI":"10.3390\/molecules26072045"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.acthis.2018.02.005","article-title":"Tetrazolium salts and formazan products in Cell Biology: Viability assessment, fluorescence imaging, and labeling perspectives","volume":"120","author":"Stockert","year":"2018","journal-title":"Acta Histochem."},{"key":"ref_38","first-page":"990","article-title":"Labeling Mitochondria with MitoTracker Dyes","volume":"2011","author":"Chazotte","year":"2011","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cell.2004.05.008","article-title":"Disruption of Mitochondrial Function during Apoptosis Is Mediated by Caspase Cleavage of the p75 Subunit of Complex I of the Electron Transport Chain","volume":"117","author":"Ricci","year":"2004","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/002215540104901010","article-title":"Mitochondrial Transmembrane Potential Changes Support the Concept of Mitochondrial Heterogeneity During Apoptosis","volume":"49","author":"Krysko","year":"2001","journal-title":"J. Histochem. Cytochem."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Gornowicz, A., Szymanowska, A., Mojzych, M., Bielawski, K., and Bielawska, A. (2020). The Effect of Novel 7-methyl-5-phenyl-pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine Sulfonamide Derivatives on Apoptosis and Autophagy in DLD-1 and HT-29 Colon Cancer Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155221"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10870-005-2805-4","article-title":"Synthesis and structure of 7-methyl-5-phenyl-1H-pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine(1)","volume":"35","author":"Mojzych","year":"2005","journal-title":"J. Chem. Crystallogr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.molstruc.2006.06.003","article-title":"Synthesis and structure of a novel mesomeric betaine 6,7-dimethyl-2H-pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine","volume":"829","author":"Karczmarzyk","year":"2007","journal-title":"J. Mol. Struct."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.molstruc.2014.03.025","article-title":"Valence tautomerism of new pyrazolo[4,3-e]tetrazole[4,5-b][1,2,4]triazines","volume":"1067","author":"Mojzych","year":"2014","journal-title":"J. Mol. Struct."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s10593-017-2157-y","article-title":"Synthesis and azido-tetrazole tautomerism of 3-azido-1,2,4-triazines","volume":"53","author":"Deev","year":"2017","journal-title":"Chem. Heterocycl. Compd."},{"key":"ref_46","unstructured":"Kasibhatla, S., Amarante-Mendes, G.P., Finucane, D., Brunner, T., Bossy-Wetzel, E., and Green, D.R. Acridine Orange\/Ethidium Bromide (AO\/EB) Staining to Detect Apoptosis. Cold Spring Harb. Protoc."},{"key":"ref_47","first-page":"102","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/jm101506n","article-title":"Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class","volume":"54","author":"Salah","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1021\/jm1003842","article-title":"Design of Selective, ATP-Competitive Inhibitors of Akt","volume":"53","author":"Autry","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1021\/jm8004527","article-title":"Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo [4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase","volume":"51","author":"Heerding","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02313-6","article-title":"Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase","volume":"8","author":"Reckel","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/pro.321","article-title":"Structures of human Bruton\u2019s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases","volume":"19","author":"Marcotte","year":"2010","journal-title":"Protein Sci."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zak\u0161auskas, A., \u010capkauskait\u0117, E., Jezep\u010dikas, L., Linkuvien\u0117, V., Paketuryt\u0117, V., Smirnov, A., Leitans, J., Kazaks, A., Dvinskis, E., and Manakova, E. (2020). Halogenated and di-substituted benzenesulfonamides as selective inhibitors of carbonic anhydrase isoforms. Eur. J. Med. Chem., 185.","DOI":"10.1016\/j.ejmech.2019.111825"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8325","DOI":"10.1158\/0008-5472.CAN-07-1826","article-title":"Meriolins, a New Class of Cell Death\u2013Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases","volume":"67","author":"Bettayeb","year":"2007","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1073\/pnas.0809645106","article-title":"Crystal structure of human CDK4 in complex with a D-type cyclin","volume":"106","author":"Day","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.str.2004.08.013","article-title":"The Crystal Structure of Human CDK7 and Its Protein Recognition Properties","volume":"12","author":"Lolli","year":"2004","journal-title":"Structure"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.chom.2017.02.009","article-title":"Structure-Guided Identification of a Family of Dual Receptor-Binding PfEMP1 that Is Associated with Cerebral Malaria","volume":"21","author":"Lennartz","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature25023","article-title":"Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40","volume":"552","author":"Yang","year":"2017","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Scaiola, A., Mangia, F., Imseng, S., Boehringer, D., Berneiser, K., Shimobayashi, M., Stuttfeld, E., Hall, M.N., Ban, N., and Maier, T. (2020). The 3.2-\u00c5 resolution structure of human mTORC2. Sci. Adv., 6.","DOI":"10.1126\/sciadv.abc1251"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1021\/acsmedchemlett.1c00033","article-title":"Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1\/PD-L1 Antagonists","volume":"12","author":"Butera","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4939-9752-7_9","article-title":"Docking with AutoDock4","volume":"2053","author":"Pintro","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s11224-020-01605-w","article-title":"Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19","volume":"31","author":"Jain","year":"2020","journal-title":"Struct. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/adt.2020.976","article-title":"Computational Drug Repurposing Approach to Identify Potential Fatty Acid-Binding Protein-4 Inhibitors to Develop Novel Antiobesity Therapy","volume":"18","author":"Mujwar","year":"2020","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/adt.2020.977","article-title":"Computational Design and Biological Depiction of Novel Naproxen Derivative","volume":"18","author":"Shah","year":"2020","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/adt.2019.943","article-title":"Molecular Docking and In Silico Cogitation Validate Mefenamic Acid Prodrugs as Human Cyclooxygenase-2 Inhibitor","volume":"17","author":"Shah","year":"2019","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1089\/adt.2019.944","article-title":"Drug Repurposing Approach for Developing Novel Therapy Against Mupirocin-Resistant Staphylococcus aureus","volume":"17","author":"Mujwar","year":"2019","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1002\/jhet.3970","article-title":"A retrospect on antimicrobial potential of thiazole scaffold","volume":"57","author":"Mishra","year":"2020","journal-title":"J. Heterocycl. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Mujwar, S., Shah, K., Gupta, J.K., and Gour, A. (2021). Docking based screening of curcumin derivatives: A novel approach in the inhibition of tubercular DHFR. Int. J. Comput. Biol. Drug Des., 14.","DOI":"10.1504\/IJCBDD.2021.118830"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/1573409915666190820144759","article-title":"Molecular Docking Based Analysis to Elucidate the DNA Topoisomerase II\u03b2 as the Potential Target for the Ganoderic Acid; A Natural Therapeutic Agent in Cancer Therapy","volume":"16","author":"Sharma","year":"2020","journal-title":"Curr. Comput. Aided-Drug Des."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Minaz, N., Razdan, R., Hammock, B.D., Mujwar, S., and Goswami, S.K. (2019). Impact of diabetes on male sexual function in streptozotocin-induced diabetic rats: Protective role of soluble epoxide hydrolase inhibitor. Biomed. Pharmacother., 115.","DOI":"10.1016\/j.biopha.2019.108897"},{"key":"ref_74","unstructured":"(2022, May 04). SwissADME. Available online: http:\/\/www.swissadme.ch."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/138920005774330639","article-title":"Cytochrome P450 Enzymes Mechanism Based Inhibitors: Common Sub-Structures and Reactivity","volume":"6","author":"Fontana","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/pr.107.07109","article-title":"Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy","volume":"60","author":"Miller","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Robinson, K., and Tiriveedhi, V. (2020). Perplexing Role of P-Glycoprotein in Tumor Microenvironment. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00265"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"19911","DOI":"10.18632\/oncotarget.24952","article-title":"Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5\/5-FU cells","volume":"9","author":"Kim","year":"2018","journal-title":"Oncotarget"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 Expression by Oncogenic Activation of the AKT\u2013mTOR Pathway in Non\u2013Small Cell Lung Cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-016-0163-8","article-title":"5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers","volume":"4","author":"Goel","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_83","first-page":"727","article-title":"PD-1\/PD-L1 Pathway: Current Researches in Cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Sun, S.-Y. (2020). Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Transl. Oncol., 13.","DOI":"10.1016\/j.tranon.2020.100847"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Langdon, S., Hughes, A., Taylor, M.A., Kuczynski, E.A., Mele, D.A., Delpuech, O., Jarvis, L., Staniszewska, A., Cosulich, S., and Carnevalli, L.S. (2018). Combination of dual mTORC1\/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. OncoImmunology, 7.","DOI":"10.1080\/2162402X.2018.1458810"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3987\/COM-04-10108","article-title":"Synthesis of Functionalized 1H-Pyrazolo[4,3-e][1,2,4]triazines and Their Fused Derivatives via Ipso-Substitution of Methylsulfonyl Group with O-, N-, S- and C-Nucleophiles","volume":"63","author":"Mojzych","year":"2004","journal-title":"Heterocycles"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1248\/bpb.25.1600","article-title":"Evaluation of the Cytotoxicity Effect of Dimethyl Sulfoxide (DMSO) on Caco2\/TC7 Colon Tumor Cell Cultures","volume":"25","author":"Zerrouk","year":"2002","journal-title":"Biol. Pharm. Bull."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-60327-017-5_2","article-title":"Flow Cytometry-Based Apoptosis Detection","volume":"Volume 559","author":"Wlodkowic","year":"2009","journal-title":"Apoptosis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.tiv.2013.11.007","article-title":"The antioxidants, vitamin A and E but not vitamin C and melatonin enhance the proapoptotic effects of irinotecan in cancer cells in vitro","volume":"28","author":"Kontek","year":"2014","journal-title":"Toxicol. Vitr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fncel.2016.00076","article-title":"Flow Cytometry-Based Assessment of Mitophagy Using MitoTracker","volume":"10","author":"Xiao","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Mujwar, S. (2021). Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2. Comput. Biol. Med., 136.","DOI":"10.1016\/j.compbiomed.2021.104748"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Daina, A., Michielin, O., and Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep., 7.","DOI":"10.1038\/srep42717"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Daina, A., and Zoete, V. (2019). Application of the SwissDrugDesign Online Resources in Virtual Screening. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184612"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/11\/5892\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:17:54Z","timestamp":1760138274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/11\/5892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":95,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["ijms23115892"],"URL":"https:\/\/doi.org\/10.3390\/ijms23115892","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]}}}